Navigation Links
Delcath to Present at the JMP Securities Research Conference
Date:5/5/2011

NEW YORK, May 5, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that management will present at The Tenth Annual JMP Securities

Research Conference on Wednesday, May 11, 2011 at 10:00 AM PT in San Francisco. Mr. David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only. Delcath will offer a live audio webcast of its presentation, which may be accessed on the Investor Relations section of the Company's website at www.delcath.com.  An archived replay of the presentation will be available for 90 days, also at www.delcath.com.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi–arm Phase II trial to treat other liver cancers. The Company received CE Mark approval for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales for the Hepatic CHEMOSAT delivery system in the EEA, if any, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales in the United States, if any, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are madeContact Information:Investor Contact:

Media Contact:Doug Sherk/Gregory Gin

Janine McCargoEVC Group

EVC Group415-896-6818/646-445-4801

646-688-0425
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
2. Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
3. Delcath to Update Investors on FDA Meeting
4. Delcath Expands Board of Directors With Appointment of Gabriel Leung
5. Delcath to Present at Upcoming Investor Conferences
6. Delcath Systems Receives Refusal to File Letter From FDA
7. Delcath Achieves ISO 13485 Certification
8. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
9. Delcath Systems Announces Third Quarter Progress Report Conference Call
10. Delcath Strengthens Research and Development Team with Key Appointments
11. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... Calif. , June 14, 2017 The ... the City of Fremont and ... of the bio-pharma industry in California ... technology, enabling executive networking, and fostering workforce development. The ... development and growth of start-ups, as well as small ...
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a ... announced Kineta Vice President of R&D and Head ... the Pandemic Preparedness for the Northwest and Beyond ... held on June 14, 2017 from 8:30-10:30 AM PDT at ... Dr. Bedard will be joined by ...
(Date:6/9/2017)... AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), ... sale and distribution of the AeroForm® Tissue Expander System, ... commercial roll-out in the United States ... hundred (100) medical institutions and health systems, located throughout ... alternative for women who choose reconstructive surgery following a ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... 2017 , ... After months of negotiations, FaceCradle USA is proud to announce the debut of ... , “Introducing our product on QVC is something we all worked hard to achieve for ... more than 90 million homes in the United States,” said FaceCradle USA President Dylan Doherty. ...
(Date:6/20/2017)... ... 20, 2017 , ... Hayes, Inc., a leading provider of ... “ 5 Questions to Ask Before Entering the Maze of Genetic Testing .” ... (GTE) team, the book explores the various types of the more than 65,000 ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Kenneth Mayer, MD, ... Society (JIAS). , Dr. Mayer, who joined the JIAS Editorial Board in 2016, ... founding Medical Research Director of Fenway Health and Co-Chair of The Fenway ...
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos Towers at Bayou ... host of new options for today’s modern senior. Brazos Towers at Bayou Manor has ... they love while offering them the services to support that lifestyle both now and ...
(Date:6/20/2017)... SAN DIEGO, California (PRWEB) , ... June 20, ... ... modern product documentation and help content solutions for the enterprise, is proud to ... web properties, including CRM, e-commerce, ticketing systems, company websites, and more to provide ...
Breaking Medicine News(10 mins):